Prodrugs of refers to an active Agent, which have the structure of General formula (i), (ii) or (iii) and characterized because z is o or NR1.The prodrugs of formulas (i) and (ii) is 0\u20134 is 0\u20134 N m l is 0 OR 1 r1 is H, alkyl, cycloalkyl, aryl, heteroaryl, aryl or heteroaryl har is, among others, R2 is H, alkyl, cycloalkyl, aryl, heteroaryl, between other R3 and R4 are independently h, alkyl, cicloa Lquilo, halogen, among others X and y are independently h, halogeno, cyano, Hydroxy,Among others and - C (o) - (chr1) n\u2013 Configuration is R or s in the prodrugs of formula (iii), N is 0 OR 1 M is 1-4 and R1 and R2 are each Halogen cr1r2 cycloalkyl or Form. In a Preferred aspect, the active Agent is an androgen, estrogen or progestin. In a Preferred aspect, the androgen is testosterone, estradiol and Estriol is an estrogen and Progestin is trimesgestona.It also relates to pharmaceutical compositions comprising these prodrugs. The prodrugs of the invention are that the most active orally Active agents of origin without change.Se refiere a profarmacos de un agente activo, que tienen la estructura general de formulas (I), (II) o (III) y que se caracterizan porque Z es O o NR1. En los profarmacos de formulas (I) y (II), n es 0–4 m es 0–4 L es 0 o 1 R1 es H, alquilo, cicloalquilo, arilo, heteroarilo, entre otros hAr es arilo o heteroarilo, entre otros R2 es H, alquilo, cicloalquilo, arilo, heteroarilo, entre otros R3 y R4 son independientemente H, alquilo, cicloalquilo, halogeno, entre otros X e Y son independientemente H, halogeno, ciano, hidroxi, entre otros y –C(O)–(CHR1)n– es una configuracion R o S. En los profarmacos de formula (III), n es 0 o 1 m es 1–4 y R1 y R2 son cada uno halogeno o CR1R2 forman cicloalquilo. En un aspecto preferido, el agente activo es un androgeno, un estrogeno o una progestina. En un aspecto mas preferido, el androgeno es testosterona el estrogeno es estradiol o estriol y la progestina es trimesgestona. Tambien se refiere a composic
